呋喃妥因(Nitrofurantoin) - 药物靶点：DNA_在研适应症：泌尿道感染_专利_临床

概要

基本信息

简介Nitrofurantoin是一种抗生素，由Procter & Gamble研发。它于1953年2月6日在美国首次获批。尼托芬妥的适应症为治疗泌尿道感染，作用机制为抑制细菌DNA的复制，从而达到杀菌的效果。常见的副作用包括恶心、食欲不振、腹泻和头痛。

药物类型

小分子化药

别名

1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione、1-((5-nitrofurfurylidene)amino)hydantoin、5-Nitrofurantoin

+ [18]

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)

治疗领域

感染泌尿生殖系统疾病

在研适应症

泌尿道感染

非在研适应症-

原研机构

Procter & Gamble Co.

在研机构

Almatica Pharma LLC

Casper Pharma LLC

非在研机构

Procter & Gamble Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1953-02-06),

泌尿道感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C8H6N4O5

InChIKeyNXFQHRVNIOXGAQ-UHFFFAOYSA-N

CAS号67-20-9

关联

47

项与呋喃妥因相关的临床试验

NCT06518291 / Not yet recruiting临床4期IIT

COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN

Fosfomycin and nitrofurantoin are increasingly being prescribed in outpatients for the oral treatment of urinary tract infection (UTI). The newest guidelines for empirical treatment of women with uncomplicated urinary tract infections (UTIs) advise clinicians to choose among three venerable antibiotics: trimethoprim-sulfamethoxazole, nitrofurantoin, and fosfomycin. Although both nitrofurantoin and fosfomycin have shown efficacy against most urinary pathogens, no recent head-to-head comparisons have been reported. So, this study will be conducted to compare effectiveness of both drugs.

开始日期2025-01-01

申办/合作机构-

CTRI/2024/10/075079 / Not yet recruitingN/AIIT

An Open Label Randomized Standard Controlled Clinical Study to Assess the Synergistic Efficacy of Two Unani Formulations in the Management of Uncomplicated Urinary Tract Infection (Tadiya-e-Aalat-e-Baul) - NIL

开始日期2024-10-15

申办/合作机构-

CTRI/2024/08/072104 / Not yet recruitingN/AIIT

Analgesic Effect Of Single Antibiotic Paste Nitrofurantoin as an Intracanal medicament– A Randomized Controlled Trial - NIL

开始日期2024-08-16

申办/合作机构-

100 项与呋喃妥因相关的临床结果

登录后查看更多信息

100 项与呋喃妥因相关的转化医学

登录后查看更多信息

100 项与呋喃妥因相关的专利（医药）

登录后查看更多信息

4,527

项与呋喃妥因相关的文献（医药）

2025-01-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Exploring the charge transfer enhancement mechanism in selective SERS detection with Mo1−W S2@Ag2S nanosheets

Article

作者: Tang, Qiao ; Dong, Qianmin ; Chen, Qing ; Huang, Jie ; Liang, Pei ; Pang, Kun

In order to solve the problem of poor sensitivity and selectivity of conventional SERS substrates, we synthesized Mo_1-xW_xS₂@Ag₂S nanosheets in this paper by a two-step hydrothermal method. The structure and morphology of the synthesized Mo_1-_xW_xS₂@Ag₂S nanosheets were characterized by XRD and SEM,respectively. The results show that the Mo_1-_xW_xS₂@Ag₂S nanosheet has an irregular layered structure. Further, the SERS properties of Mo_1-_xW_xS₂@Ag₂S nanosheets were tested by using rhodamine 6G (R6G), crystalline violet (CV), and 4-mercaptobenzoic acid (4-MBA) as probe molecules, respectively. The test results demonstrated that the nanosheets were specific to R6G and CV probe molecules, and the mechanism of selectivity was due to CT enhancement. In addition, Mo_1-_xW_xS₂@Ag₂S exhibits ultrahigh sensitivity in R6G and CV, with the corresponding detection limit of both reached 10^-8 M. And linear fitting of the peak intensities was carried out, with the R² coefficient of 0.981 and 0.951, respectively. Finally, the relative standard deviations (RSDs) of this Mo1-xWxS2@Ag2S nanosheets was obtained to be 8.56 % by test 1 × 10^-4 M R6G at the characteristic peak 613 cm^-1, which represents excellent detection repeatability. The Mo_1-_xW_xS₂@Ag₂S nanosheets are rich in edge-active sites favorable for charge transfer, which can enhance the SERS signals of the target molecules better. Besides, the Raman detection of the surface of Mo_1-_xW_xS₂@Ag₂S nanosheets using nitrofurantoin (NFT) also reached a detection limit of 10^-8 M. Mo_1-_xW_xS₂@Ag₂S nanosheets substrates can find applications in medicine and provide new strategies for improving the SERS performance.

2024-12-31·Future Science OA

Antimicrobial resistance pattern and uropathogens distribution in children visiting a referral hospital in Mogadishu

Article

作者: Kassim, Mohamed Muktar ; Mohamed, Abdikarin Ahmed ; Yusuf, Abdisalam Abdullahi ; Bastug, Yavuz ; Mohamed, Abdikarim Hussein ; Senol, Cem

Aim: Studies concerning epidemiology and drug susceptibility patterns of pediatric urinary tract infection in developing countries are scarce. This study aimed to evaluate the antimicrobial resistance pattern and uropathogens distribution in children. Method: Four-year retrospective study included 840 participants in all pediatric age groups whose urine had been cultured. Results: The prevalence of culture-proven pediatric UTIs was 17.6% (148/840). Escherichia coli was the most common pathogen isolated from the cultures, accounting for (48%, 71/148), followed by Klebsiella pneumoniae (16.2%, 24/148). About 27% of the pathogens had a multidrug-resistant (MDR) pattern. A resistance rate against nitrofurantoin at 24.6%, fosfomycin at 15.2% and trimethoprim-sulfamethoxazole (SMX-TMP) at 79.7% was noted. Conclusion: E. coli and Klebsiella pneumoniae were the most common pathogens isolated.

2024-12-31·Virulence

Tobramycin-resistant small colony variant mutant of Salmonella enterica serovar Typhimurium shows collateral sensitivity to nitrofurantoin

Article

作者: Long, Teng-Fei ; Chu, Yue-Fei ; Zhong, Long-Gen ; Wang, Chang-Zhen ; Liang, Liu-Yan ; Fang, Liang-Xing ; Zhou, Yu-Feng ; Xu, Jin-Peng ; Liao, Xiao-Ping ; Zhang, Yue-Jun ; Sun, Jian

The increasing antibiotic resistance poses a significant global health challenge, threatening our ability to combat infectious diseases. The phenomenon of collateral sensitivity, whereby resistance to one antibiotic is accompanied by increased sensitivity to another, offers potential avenues for novel therapeutic interventions against infections unresponsive to classical treatments. In this study, we elucidate the emergence of tobramycin (TOB)-resistant small colony variants (SCVs) due to mutations in the hemL gene, which render S. Typhimurium more susceptible to nitrofurantoin (NIT). Mechanistic studies demonstrate that the collateral sensitivity in TOB-resistant S. Typhimurium SCVs primarily stems from disruptions in haem biosynthesis. This leads to dysfunction in the electron transport chain (ETC) and redox imbalance, ultimately inducing lethal accumulation of reactive oxygen species (ROS). Additionally, the upregulation of nfsA/B expressions facilitates the conversion of NIT prodrug into its active form, promoting ROS-mediated bacterial killing and contributing to this collateral sensitivity pattern. Importantly, alternative NIT therapy demonstrates a significant reduction of bacterial load by more than 2.24-log₁₀ cfu/g in the murine thigh infection and colitis models. Our findings corroborate the collateral sensitivity of S. Typhimurium to nitrofurans as a consequence of evolving resistance to aminoglycosides. This provides a promising approach for treating infections due to aminoglycoside-resistant strains.

37

项与呋喃妥因相关的新闻（医药）

2024-11-04

·drugs

Nitrofurantoin, Cranberry Products May Cut UTI Episodes in Children

MONDAY, Nov. 4, 2024 -- For children with a history of recurrent urinary tract infection (RUTI), nitrofurantoin and cranberry products may reduce the incidence of symptomatic UTI episodes, according to a review published online Nov. 4 in Pediatrics . Nikolaos Gkiourtzis, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review of randomized controlled trials comparing prophylaxis options for the prevention of UTI and kidney scarring in children with a history of RUTI. A total of 3,335 participants from 23 studies were included in the meta-analysis. The researchers found that cranberry products (compared with the control group) and nitrofurantoin (compared with the control, trimethoprim-sulfamethoxazole, or trimethoprim groups) led to lower odds of symptomatic UTI episodes during prophylaxis. Compared with all available documented interventions, nitrofurantoin appeared to be the best option for reduction in the incidence of UTI. None of the prophylaxis options showed a reduction in kidney scarring. "Future studies with optimal methodology, studying nonantibiotic prophylaxis options, focusing on children with RUTI, and the risk for kidney scarring are needed to draw further conclusions," the authors write. Abstract/Full Text Editorial (subscription or payment may be required) Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-10-18

·PMLiVE

GSK’s investigational antibiotic granted FDA priority review for urinary tract infections

GSK’s new drug application for its investigational oral antibiotic gepotidacin has been accepted for priority review by the US Food and Drug Administration (FDA) to treat uncomplicated urinary tract infections (uUTIs). The regulator is expected to make a decision on gepotidacin, which could be the first in a new class of oral antibiotics for uUTIs in over 20 years, by 26 March 2025. GSK is specifically seeking approval of the drug to treat female adults and adolescents aged 12 years and older and weighing at least 40kg. More than half of women are affected by uUTIs in their lifetime, with approximately 30% experiencing recurrent disease. Additionally, the number of uUTIs caused by drug-resistant bacteria is increasing, underscoring the need for new treatment options. Gepotidacin’s distinct mechanism of action provides activity against most target uropathogens, such as E. coli and S. saprophyticus, including isolates resistant to current antibiotics. GSK’s application for the drug is supported by positive results from the late-stage EAGLE-2 and EAGLE-3 trials, in which gepotidacin demonstrated non-inferiority to nitrofurantoin, the current standard of care, in female adults and adolescents with a confirmed uUTI and a uropathogen susceptible to nitrofurantoin. The safety and tolerability profile of gepotidacin in the EAGLE-2 and EAGLE-3 was also shown to be consistent with previous trials of the drug. Designated by the World Health Organization as one of the top ten threats to global public health, AMR occurs when bacteria, viruses, fungi and parasites change and find ways to resist the effects of antimicrobial drugs. As a result, infections become harder to treat and the risk of serious complications and death increases. GSK became the first founding partner of the Fleming Initiative, a new global network aimed at tackling AMR, earlier this year. The company’s chief executive officer, Emma Walmsley, said at the time of the May announcement: “The Fleming Initiative will bring together global resources and expertise from across different sectors to better understand the factors contributing to this growing threat and, most importantly, drive action and solutions. We are proud to be a founding partner and hope others will join us to support this urgent priority.”

优先审批临床结果合格传染病产品临床3期

2024-10-16

·药明康德

有望成为20年来首款！GSK潜在"first-in-class"小分子疗法获FDA优先审评资格

▎药明康德内容团队编辑 GSK今天宣布，美国FDA已接受其潜在"first-in-class"口服抗生素gepotidacin的新药申请（NDA），用于治疗患有单纯性尿路感染（uUTI，也称为急性膀胱炎）成年或青少年（≥12岁）女性患者，患者体重须≥40公斤。FDA授予该申请优先审评资格，并预计在2025年3月26日前完成审评。根据新闻稿，若获批，gepotidacin将成为20多年来首个用于治疗uUTI的新型口服抗生素药物。超过一半的女性一生中会罹患uUTI，其中约30%的女性会发生复发。由于耐药细菌引起的uUTI病例不断增加，可能导致更高的治疗失败率，因此急需开发新的治疗方法。该新药申请得到了关键性3期EAGLE-2和EAGLE-3试验积极结果的支持。在这些研究中，与目前uUTI标准疗法nitrofurantoin抗生素相比，gepotidacin在治疗确诊的uUTI成年与青少年女性患者中展现非劣效性，这些患者已知对nitrofurantoin应答。 ▲Gepotidacin分子结构（图片来源：PubChem）在EAGLE-3试验中，gepotidacin与活性对照药物相比具有统计学显著优势，58.5%（n=162/277）的gepotidacin组患者治疗成功，而此数值在活性对照药物组中为43.6%（n=115/264，差异14.6%，95% CI：6.4~22.8）。在EAGLE-2试验中，50.6%（n=162/320）的gepotidacin组患者显示出治疗成功，而此数值在活性对照组中为47.0%（n=135/287，差异4.3%，95% CI：-3.6~12.1）。 Gepotidacin在EAGLE-2和EAGLE-3试验中的安全性和耐受性结果与先前试验一致。 Gepotidacin是一款具有全新作用机制的抗生素，它可以口服，并具有双重作用机制，能同时选择性地结合并抑制DNA促旋酶和DNA拓扑异构酶IV，从而诱发在复制进程的DNA发生单链断裂，进而达到杀死病原体的目的。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents. Retrieved October 16, 2024 from https://www.gsk.com/en-gb/media/press-releases/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批临床结果临床3期

100 项与呋喃妥因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00439	呋喃妥因	J01XE01	DB00698

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
泌尿道感染	美国	Casper Pharma LLC	1953-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2023	N/A	慢性肺疾病 \| 间质性肺疾病	-	Nitrofurantoin	(築構範艱艱簾鹽觸鹽鑰) = 窪網膚製築積鹹遞觸窪遞願簾製鑰廠願製鏇觸 (壓鑰艱遞蓋餘廠壓壓夢 ) 更多	-	2023-05-21
NCT03287089 (Pubmed \| Female Pelvic Med Reconstr Surg)	临床4期	-	164	Nitrofurantoin	(願積齋觸膚廠遞淵憲獵) = 夢鏇齋窪膚夢積網餘範壓膚鏇齋糧網鬱衊簾構 (廠網窪醖廠繭淵製壓夢 )	不佳	2021-03-01
				Placebo	(願積齋觸膚廠遞淵憲獵) = 淵淵膚簾壓餘衊製簾獵壓膚鏇齋糧網鬱衊簾構 (廠網窪醖廠繭淵製壓夢 )
NCT03287089 (NAUTICA, CTgov)	临床4期	导管相关感染	164	Nitrofurantoin 100 MG (Nitrofurantoin)	夢獵衊鹹鏇醖選顧廠範(鹹淵衊願廠簾範齋鏇簾) = 鏇襯遞鬱艱鹹糧餘襯顧觸製齋蓋衊淵壓窪鑰糧 (鹽遞壓淵淵觸鬱遞遞獵, 築鏇餘廠糧遞夢鬱網衊 ~ 鏇鹹觸鑰壓鏇壓襯淵憲) 更多	-	2020-06-09
				Placebo Oral Tablet (Placebo)	夢獵衊鹹鏇醖選顧廠範(鹹淵衊願廠簾範齋鏇簾) = 顧衊遞積選膚鏇鏇願糧觸製齋蓋衊淵壓窪鑰糧 (鹽遞壓淵淵觸鬱遞遞獵, 積簾衊築襯鏇夢範願蓋 ~ 製淵網憲餘選憲選鬱夢) 更多
NCT02727322 (CTgov)	临床4期	盆腔脏器脱垂 \| 急性尿潴留	154	Nitrofurantoin (Nitrofurantoin)	獵鬱壓鏇繭積鑰齋夢膚(膚簾鹽選構鹹鹽餘襯壓) = 襯範憲醖夢糧蓋廠窪齋鹹鏇糧夢鹽簾構範膚選 (鹹蓋夢鏇廠獵顧網積廠, 鏇夢衊廠鑰廠製艱醖糧 ~ 鹽獵鬱憲選膚壓觸衊齋) 更多	-	2019-05-20
				Placebo (Placebo)	獵鬱壓鏇繭積鑰齋夢膚(膚簾鹽選構鹹鹽餘襯壓) = 夢獵網淵簾醖網夢簾鹹鹹鏇糧夢鹽簾構範膚選 (鹹蓋夢鏇廠獵顧網積廠, 顧築構壓構鏇醖壓壓獵 ~ 糧壓鏇觸製積餘製襯鹹) 更多
AUA2019	N/A	-	221	NITROFURANTOIN (Neurogenic post-menopausal women)	壓繭觸艱鹽鑰淵網淵選(繭衊膚廠顧齋願齋鹹願) = 鬱構製製蓋蓋鑰壓製選觸艱蓋範構簾夢遞網衊 (衊壓網餘遞構繭選觸餘 )	-	2019-04-01
				NITROFURANTOIN (Non-neurogenic post-menopausal women)	壓繭觸艱鹽鑰淵網淵選(繭衊膚廠顧齋願齋鹹願) = 構醖膚夢鹽齋蓋獵蓋廠觸艱蓋範構簾夢遞網衊 (衊壓網餘遞構繭選觸餘 )
NCT01749605 (CTgov)	临床4期	膀胱炎	35	Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days (Nitrofurantoin 100 mg)	齋糧簾夢壓製廠鑰鏇鏇(願艱觸觸鬱製膚餘積醖) = 網選餘憲鬱壓廠鬱糧艱淵鏇衊鑰膚糧鹹鏇遞廠 (簾衊積願襯蓋簾鹹壓齋, 襯淵鬱憲憲廠膚艱願夢 ~ 憲鹽積築鏇積鏇選醖艱) 更多	-	2017-04-27
				ciprofloxacin 250 mg BID x 3 days (Ciprofloxacin 250 mg)	齋糧簾夢壓製廠鑰鏇鏇(願艱觸觸鬱製膚餘積醖) = 範鏇艱鏇餘選獵積鏇膚淵鏇衊鑰膚糧鹹鏇遞廠 (簾衊積願襯蓋簾鹹壓齋, 衊膚齋繭醖構鬱築願願 ~ 築憲觸襯範鹽鏇鏇製鑰) 更多
NCT00734968 (CTgov)	临床4期	泌尿道感染 \| 压力性尿失禁	161	Nitrofurantoin (Treatment)	鹽製衊鬱顧衊艱襯積簾(網廠構繭夢鏇築範餘觸) = 齋鹹鬱齋簾衊構蓋顧糧壓衊願築夢觸遞簾糧廠 (繭遞蓋廠網窪鹹觸襯願, 遞艱遞遞艱鹽齋築遞築 ~ 鏇淵顧築艱觸鹽製顧遞) 更多	-	2016-10-11
				Placebo (Placebo)	鹽製衊鬱顧衊艱襯積簾(網廠構繭夢鏇築範餘觸) = 範鏇艱鹽築鬱窪衊積選壓衊願築夢觸遞簾糧廠 (繭遞蓋廠網窪鹹觸襯願, 糧構鏇遞鏇築膚願艱壓 ~ 網膚鹹夢繭顧醖簾鏇膚) 更多
ERS2016	N/A	肺部疾病	26	nitrofurantoin	膚範築繭蓋鑰襯糧鬱淵(獵衊鹹繭鑰鑰夢壓構襯) = 窪築獵遞築網壓鏇獵餘淵鑰鹽願遞積選鹹構廠 (鬱鑰膚鑰製憲網廠選艱 )	-	2016-09-01
				nitrofurantoin	膚範築繭蓋鑰襯糧鬱淵(獵衊鹹繭鑰鑰夢壓構襯) = 壓蓋選顧構廠憲艱鏇襯淵鑰鹽願遞積選鹹構廠 (鬱鑰膚鑰製憲網廠選艱 )
NCT02789579 \| NCT02829060 (Pubmed \| Urology)	早期临床1期	呼吸道感染 \| 尿脓毒症	101	Nitrofurantoin prophylaxis	膚膚淵艱獵選顧構鑰遞(窪艱網積築顧遞鹽簾憲) = 淵獵觸選夢衊醖廠構鏇蓋蓋選衊憲鬱選選糧淵 (醖顧網鹽願觸獵醖艱範 ) 更多	积极	2011-01-01
ISRCTN11966080 (Pubmed \| Obstet Gynecol)	临床3期	妊娠期无症状菌尿	778	1-day nitrofurantoin regimen	積襯網鹹顧襯廠窪遞醖(淵膚範艱鑰範餘鑰選繭) = 憲醖蓋膚壓網積壓壓淵觸觸鏇窪製壓製觸簾選 (鹹積願鏇製鹹衊鹽衊衊 )	不佳	2009-02-01
				7-day nitrofurantoin regimen	積襯網鹹顧襯廠窪遞醖(淵膚範艱鑰範餘鑰選繭) = 鹽選餘糧範願獵鏇簾鹹觸觸鏇窪製壓製觸簾選 (鹹積願鏇製鹹衊鹽衊衊 )